Recombinant Acanthamoeba polyphaga mimivirus Uncharacterized protein L536 (MIMI_L536)

How does MIMI_L536 compare to other mimivirus proteins?

Unlike characterized mimivirus proteins such as gp275 (which functions as an MC1-like non-histone architectural protein involved in DNA condensation) or L375 (a Nudix enzyme that hydrolyzes the 5' mRNA cap), MIMI_L536 remains functionally uncharacterized .

Comparative analysis table of selected mimivirus proteins:

This comparison highlights the current knowledge gap regarding MIMI_L536 compared to other mimivirus proteins that have defined functions in the viral replication cycle .

How should I design experiments to determine the function of MIMI_L536?

A comprehensive experimental design approach should include:

• Gene knockout studies:

  • Generate a knockout mutant using homologous recombination in Acanthamoeba cells

  • Design complementation experiments with transgenic Acanthamoeba lines expressing a codon-optimized version of MIMI_L536

  • Compare viral replication efficiency, viral factory formation, and virion production between wild-type and knockout viruses

• Protein localization studies:

  • Create fluorescent protein fusions (e.g., EGFP-tagged MIMI_L536)

  • Perform time-course infection experiments using fluorescence microscopy

  • Co-localize with known viral factory markers like DAPI (DNA) and other tagged proteins

• Protein-protein interaction studies:

  • Conduct co-immunoprecipitation experiments using formaldehyde crosslinking

  • Perform mass spectrometry analysis to identify binding partners

  • Verify interactions with candidate proteins using techniques like fluorescence resonance energy transfer (FRET)

This multifaceted approach follows established protocols that have successfully characterized other mimivirus proteins such as gp275 and viral factory scaffold proteins .

What controls are essential when working with recombinant MIMI_L536?

When working with recombinant MIMI_L536, include these critical controls:

• Expression controls:

  • Empty vector control expressing the same tag without MIMI_L536

  • Expression of a well-characterized mimivirus protein (e.g., gp455) with the same tag

  • Wild-type untagged control

• Functional assays controls:

  • Positive control: Known DNA-binding protein (if testing DNA interactions)

  • Negative control: Non-relevant protein expressed under identical conditions

  • Buffer-only control

• Localization experiment controls:

  • GFP or RFP-only expression to control for random localization

  • Co-expression with known viral factory proteins (e.g., gp455-RFP)

  • DAPI staining to visualize DNA in the viral factory

These controls are based on methodologies successfully employed in studies of mimivirus protein gp275, where researchers used tagged gp455 as a control and co-localization marker .

How can I optimize protein expression conditions for MIMI_L536?

Based on successful expression of other mimivirus proteins, consider these methodological approaches:

• E. coli expression system optimization:

  • Test multiple E. coli strains (BL21(DE3), Rosetta, Arctic Express)

  • Vary induction parameters: IPTG concentration (0.1-1.0 mM), temperature (16°C, 25°C, 37°C), and duration (4h vs. overnight)

  • Compare solubility with different fusion tags (His, GST, MBP, SUMO)

• Expression condition screening:

  E. coli Strain	Temperature	IPTG Concentration	Induction Time	Expected Outcome
  BL21(DE3)	37°C	1.0 mM	4 hours	High expression, possible inclusion bodies
  BL21(DE3)	16°C	0.1 mM	Overnight	Lower expression, higher solubility
  Rosetta	25°C	0.5 mM	6 hours	Moderate expression, improved folding

• Purification strategy:

  • Initial IMAC purification (for His-tagged protein)

  • Secondary purification step (ion exchange or size exclusion chromatography)

  • Buffer optimization to maintain protein stability

This approach is based on established protocols for recombinant expression of mimivirus proteins such as ILS1 and OLS1, which were successfully expressed and purified from E. coli for functional studies .

How can I determine if MIMI_L536 interacts with viral or host DNA?

To characterize potential DNA interactions:

• In vitro DNA binding assays:

  • Electrophoretic mobility shift assay (EMSA) with labeled DNA fragments

  • DNA protection assay using DNase I footprinting

  • Surface plasmon resonance (SPR) to measure binding kinetics

• DNA specificity testing:

  • Compare binding to viral genomic DNA vs. host DNA

  • Test different DNA structures (linear, circular, single-stranded)

  • Vary DNA concentration to assess concentration dependence, as observed with ILS1

• Microscopy-based approaches:

  • Co-localization of fluorescently-tagged MIMI_L536 with DNA during infection

  • Live-cell imaging using techniques like EU (for RNA) or EdU (for DNA) labeling

  • Super-resolution microscopy to precisely locate MIMI_L536 within viral factories

Apply methodological considerations demonstrated with ILS1, which showed DNA-dependent phase separation that varied with DNA concentration and topology .

What approaches can reveal if MIMI_L536 undergoes phase separation in viral factories?

Based on recent findings with mimivirus scaffold proteins:

• In vitro phase separation assays:

  • Test recombinant MIMI_L536 at different concentrations (50-500 μM)

  • Vary buffer conditions (salt concentration, pH, temperature)

  • Add potential co-factors (DNA, RNA, other viral proteins)

  • Use microscopy to visualize biomolecular condensate formation

• Quantitative analysis:

  MIMI_L536 Concentration	Salt Concentration	DNA Present	Expected Outcome
  100 μM	150 mM NaCl	No	Test for intrinsic phase separation
  100 μM	150 mM NaCl	Yes	Test for DNA-enhanced phase separation
  100 μM	500 mM NaCl	Yes	Test salt sensitivity of condensates

• In vivo approaches:

  • Express fluorescently-tagged MIMI_L536 in Acanthamoeba

  • Use fluorescence recovery after photobleaching (FRAP) to assess protein dynamics

  • Co-express with known phase-separating proteins like OLS1 to test for co-condensation

This methodological approach is based on successful phase separation studies of mimivirus proteins OLS1 and ILS1, which form the scaffold of viral factories through phase separation .

How might MIMI_L536 contribute to the mimivirus replication cycle?

Based on studies of other mimivirus proteins, several hypotheses can be tested:

• Potential roles in viral factory formation:

  • Co-localization with viral factory markers at different time points (6h, 8h post-infection)

  • Knockout impact on viral factory morphology and development

  • Interaction with known viral factory proteins like OLS1 or ILS1

• Possible involvement in viral genome processes:

  • DNA binding and condensation (similar to gp275)

  • RNA processing or cap modification (similar to L375)

  • Structural role in virion assembly

• Systematic testing methodology:

  • Time-course expression analysis during infection

  • Mass spectrometry to identify MIMI_L536 in different viral compartments

  • Functional complementation assays with knockout viruses

These approaches mirror successful functional characterization of other mimivirus proteins, such as gp275, which was shown to be essential through knockout experiments and localized to viral factories through microscopy .

What are the optimal strategies for purifying recombinant MIMI_L536?

Based on successful purification of other mimivirus proteins:

• Expression and initial purification:

  • His-tagged MIMI_L536 expression in E. coli

  • Lysis in appropriate buffer (e.g., 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM imidazole)

  • Initial purification using Ni-NTA affinity chromatography

• Advanced purification:

  • Size exclusion chromatography to remove aggregates and ensure homogeneity

  • Ion exchange chromatography if additional purity is required

  • Consider tag removal if the tag interferes with functional assays

• Quality control assessment:

  • SDS-PAGE to verify purity (aim for >95%)

  • Western blot to confirm identity

  • Dynamic light scattering to assess homogeneity

  • Mass spectrometry to confirm molecular weight and sequence

This purification strategy is based on protocols used for successful purification of mimivirus proteins like ILS1 and OLS1 for in vitro functional studies .

How can I design gene knockout experiments for MIMI_L536?

Based on successful mimivirus gene knockout strategies:

• Knockout construct design:

  • Homologous recombination strategy with flanking regions (~500bp each)

  • Replace MIMI_L536 with a selectable marker or fluorescent reporter

  • Design PCR primers for screening recombinant viruses

• Transfection and selection approach:

  • Generate trans-complementing Acanthamoeba cell line expressing codon-optimized MIMI_L536

  • Transfect knockout construct into Acanthamoeba cells

  • Isolate and verify recombinant viruses through PCR and sequencing

• Phenotypic analysis:

  • Compare viral replication in wild-type vs. complementing cells

  • Assess viral factory formation using DAPI staining

  • Quantify viral particle production by flow cytometry and electron microscopy

This approach follows the methodology used for successful knockout of OLS1, which demonstrated its importance in viral factory formation and viral replication .

What microscopy techniques are most informative for studying MIMI_L536 localization?

Recommended microscopy approaches based on successful mimivirus studies:

• Fluorescence microscopy methods:

  • Confocal microscopy for co-localization with viral factory markers

  • Live-cell imaging to track dynamics during infection

  • Super-resolution microscopy (STED, STORM) for precise localization

• Sample preparation protocols:

  • Fixed samples: 4% paraformaldehyde fixation, permeabilization with 0.1% Triton X-100

  • Live imaging: Expression of fluorescent protein fusions in Acanthamoeba cells

  • Specific labeling: Use antibodies against MIMI_L536 or epitope tags

• Quantitative analysis:

  • Co-localization coefficients (Pearson's, Mander's)

  • Time-course intensity measurements

  • FRAP analysis for protein dynamics

These methods are based on successful approaches used to study the localization of gp275-EGFP and gp455-RFP in mimivirus-infected cells, which revealed their co-localization with viral DNA in the viral factory .

How can computational approaches predict MIMI_L536 function?

Advanced computational strategies include:

• Structural prediction methods:

  • AlphaFold2 or RoseTTAFold for 3D structure prediction

  • Molecular dynamics simulations to study protein flexibility

  • Template-based modeling using structures of related proteins

• Functional prediction approaches:

  • Sequence motif identification using MEME, PROSITE

  • Comparative genomics across different mimiviruses

  • Protein-protein interaction prediction with STRING, STITCH

• Integrative analysis workflow:

  • Initial sequence analysis (conserved domains, disorder prediction)

  • Secondary structure prediction and fold recognition

  • 3D structure modeling and validation

  • Function prediction based on structural similarities

These computational approaches can provide valuable hypotheses about MIMI_L536 function to guide experimental design, similar to the identification of the MC1 domain in gp275 which led to its characterization as a DNA architectural protein .

How might MIMI_L536 interact with the phase-separated viral factory?

Based on recent advances in understanding mimivirus viral factories:

• Phase separation interaction studies:

  • Test co-phase separation with OLS1 and ILS1 in vitro

  • Examine recruitment to pre-formed biomolecular condensates

  • Analyze partition coefficients in different phases of the viral factory

• Localization within the viral factory architecture:

  • Determine if MIMI_L536 localizes to the inner layer (IL) or outer layer (OL)

  • Test interaction with DNA within the viral factory

  • Analyze temporal dynamics during viral factory development

• Functional impact assessment:

  • Evaluate effect of MIMI_L536 on phase separation properties of viral factory components

  • Test impact on viral processes (replication, transcription) within the viral factory

  • Analyze recruitment of other viral or host factors to the viral factory

This research direction builds on recent findings about the biphasic nature of mimivirus viral factories, where proteins like OLS1 and ILS1 create distinct layers through phase separation processes .

What advanced mass spectrometry approaches can identify MIMI_L536 post-translational modifications?

State-of-the-art mass spectrometry approaches include:

• Sample preparation strategies:

  • Enrichment of MIMI_L536 through immunoprecipitation

  • Specific digestion methods (trypsin, chymotrypsin, GluC)

  • Phosphopeptide enrichment using TiO₂ or IMAC

• MS analysis methods:

  • LC-MS/MS using high-resolution instruments (Orbitrap, Q-TOF)

  • Multiple fragmentation methods (HCD, ETD, EThcD)

  • Data-independent acquisition (DIA) for comprehensive coverage

• Data analysis workflow:

  • Database searching with variable modifications

  • Spectral validation and manual verification

  • Quantification of modification stoichiometry

This approach is based on successful MS identification of mimivirus proteins in complex samples, such as the identification of L442, L724, L829, R387, and R135 in DNA-associated protein fractions .